NF-kappaB and MAP Kinase Signaling in Inflammation
joint with Ubiquitin Signaling
Organizer(s): Steven C. Ley, Zhijian 'James' Chen and Jenny P.Y. TingDate: March 13 - 17, 2016
Location: Whistler Conference Centre, Whistler, BC, Canada
Dysregulated inflammatory responses underlie many major diseases, including arthritis, psoriasis, inflammatory bowel disease, atherosclerosis, metabolic disease and cancer. Consequently, there is considerable interest in the pharmaceutical industry in targeting the signaling pathways regulating inflammation as a potential therapeutic approach for treatment of these diseases. Gene expression during inflammatory responses is controlled by NF-kappaB transcription factors, IRF transcription factors and each of the major MAP kinase subtypes (ERK1/2, JNK and p38) in innate immune cells. This symposium will focus on the role of ubiquitination in regulating NF-kappaB and MAP kinase activation, and how NF-kappaB-dependent transcription is coordinated with IRF activation and MAP kinase signaling to control innate immunity. Progress in the therapeutic targeting of NF-kappaB and MAP kinase activation pathways for treatment of chronic inflammatory diseases and cancer will also be discussed.
Scholarship Deadline: November 11 2015
Discounted Abstract Deadline: November 11 2015
Abstract Deadline: December 14 2015
Discounted Registration Deadline: January 13 2016
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We gratefully acknowledge the generous grant for this conference provided by:National Institute of Allergy and Infectious Diseases (NIAID)
Grant No. 1R13AI122450-01
Funding for this conference was made possible (in part) by 1 R13 AI 122450 - 01 from the National Institute of Allergy and Infectious Diseases. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.